Page 4 - Data Review News Today

Mansfield, MA (PRWEB) May 26, 2021 -- Mansfield, MA, May 26, 2021 — eClinical Solutions LLC, a global provider of cloud-based enterprise software and

Clark Freight Lines, with 180 trucks, used to routinely file lots of DataQs RDRs (Requests for Data Review) but met with little success, said Vice President Danny Schnautz. He gave the example of a violation for an air leak that wasn’t in fact a safety violation. “What we found out was it made the police department really mad,” he said, particularly when the challenge was filed with little in the way of hard evidence. “Now we don’t dispute it unless we have real proof.” Depen...

(** B P) War economy flourishing behind the walls of Houthis detention centers Among the group of detainees who were released by paying money to Houthi mediators or supervisors spoke with Almasdar Online, Al-Sabri was the only one who agreed to disclose his name. The others asked to remain anonymous to protect themselves and their relatives who still live in Houthi-controlled areas from retribution. Other former detainees categorically refused to tell their stories for this report, out of fear ...

Ulcerative Colitis Phase II Study of GSK2831781 Discontinued Immutep’s Collaboration and Exclusive License with GSK Remains in Place January 21, 2021 17:40 ET | Source: Immutep Limited Immutep Limited Sydney, AUSTRALIA Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoim...

Immutep: GlaxoSmithKline Discontinues Phase II Study On Ulcerative Colitis LONDON (dpa-AFX) - Immutep Limited (IMMP) said that its licensing partner GlaxoSmithKline plc. (GSK.L, GSK) has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, in patients with active ulcerative colitis. GlaxoSmithKline stopped the trial based on the assessment of clinical data as part of a planned interim analysis conducted in consultation with the trials ...

TACTI-002 study expanded in lung cancer New phase II trial in head and neck cancer announced EOC Pharma starts new phase II study in metastatic breast cancer Robust operational and financial position, with $54.9 million in cash as at 31 December 2020, providing cash runway beyond the end of calendar year 2022 Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy...